News
ABVX
88.15
-1.01%
-0.90
Cedar Grove Capital Q3 2026 Portfolio Update
Seeking Alpha · 4d ago
Notable ETF Inflow Detected - VEA, GFL, ABVX, SHOP
NASDAQ · 5d ago
Weekly Report: what happened at ABVX last week (0928-1002)?
Weekly Report · 6d ago
BTIG Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)
TipRanks · 10/02 10:26
Abivax To Present Seven Scientific Abstracts On Obefazimod, Lead Drug Candidate For Treatment Of Active Ulcerative Colitis At UEG Week 2026 Meeting
Benzinga · 09/30 20:16
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Barchart · 09/30 15:05
Abivax: Robust Obefazimod UC Data Reinforce Long-Term Upside as Harrison Reiterates Buy and Keeps $175 Price Target Unchanged
TipRanks · 09/29 09:56
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and Medtronic (MDT)
TipRanks · 09/28 11:20
Weekly Report: what happened at ABVX last week (0921-0925)?
Weekly Report · 09/28 09:26
Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts
Seeking Alpha · 09/23 17:00
Midday Fly By: AutoZone reports Q4 beat, Binance invests in Circle Internet
TipRanks · 09/22 15:55
BTIG Reiterates Buy on Abivax, Maintains $175 Price Target
Benzinga · 09/22 15:30
Analysts’ Top Healthcare Picks: Abivax SA Sponsored ADR (ABVX), Biodesix (BDSX)
TipRanks · 09/22 13:50
These Analysts Slash Their Forecasts On Abivax Following H1 Results
Benzinga · 09/22 13:28
Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151
Benzinga · 09/22 13:19
Wedbush Maintains Neutral on Abivax, Lowers Price Target to $118
Benzinga · 09/22 12:40
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and NewAmsterdam Pharma Company (NAMS)
TipRanks · 09/22 12:20
Abivax price target lowered to $118 from $140 at Wedbush
TipRanks · 09/22 11:55
Abivax price target lowered to $151 from $155 at Truist
TipRanks · 09/22 11:30
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and Eli Lilly & Co (LLY)
TipRanks · 09/22 11:30
More
Webull provides a variety of real-time ABVX stock news. You can receive the latest news about Abivax S.A. through multiple platforms. This information may help you make smarter investment decisions.
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.